| Experience with rufinamide in a pediatric population: a single center's experience. | |
| | |
MedLine Citation:
|
PMID: 20691934 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Rufinamide is a new antiepileptic drug recently approved as adjunctive treatment for generalized seizures in Lennox-Gastaut syndrome. We undertook a retrospective analysis of 77 patients with refractory epilepsy and receiving rufinamide to evaluate the drug's efficacy, tolerability, safety, and dosing schedules. It appeared efficacious in diverse epilepsy syndromes, with the highest responder rate in focal cryptogenic epilepsies (81.1% of patients with >50% response rate), and in diverse seizure types, with the highest responder rate in tonic/atonic and partial seizures (48.6% and 46.7% of patients with >50% response rate, respectively). Rufinamide was well tolerated: only 13% of patients developed side effects necessitating drug withdrawal. These findings suggest that rufinamide may possess good efficacy and tolerability, and that its efficacy may extend to epilepsy syndromes beyond Lennox-Gastaut, including both partial and generalized epilepsy syndromes. |
| | |
Authors:
|
Martina Vendrame; Tobias Loddenkemper; Vasu D Gooty; Masanori Takeoka; Alexander Rotenberg; Ann M Bergin; Yaman Z Eksioglu; Annapurna Poduri; Frank H Duffy; Mark Libenson; Blaise F Bourgeois; Sanjeev V Kothare |
Related Documents
:
|
9578524 - Quantitative mri in outpatient childhood epilepsy. 15145314 - Unilateral spatial neglect following right inferior parietal cortectomy. 10999554 - Tonic seizures: their significance for lateralization and frequency in different focal ... 20643614 - Partial epilepsy complicated by convulsive and nonconvulsive episodes of status epilept... 4052714 - The spectrum of the oro-facial digital syndrome. 22555754 - Heart failure and cardiogenic shock associated with the tb-immune reconstitution inflam... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Pediatric neurology Volume: 43 ISSN: 1873-5150 ISO Abbreviation: Pediatr. Neurol. Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-08-09 Completed Date: 2010-12-06 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8508183 Medline TA: Pediatr Neurol Country: United States |
Other Details:
|
Languages: eng Pagination: 155-8 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Anticonvulsants / therapeutic use* Child Child, Preschool Epilepsy / drug therapy*, physiopathology Female Humans Infant Male Pediatrics Retrospective Studies Seizures / drug therapy, physiopathology Treatment Outcome Triazoles / therapeutic use* Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Anticonvulsants; 0/Triazoles; 106308-44-5/rufinamide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dual-Energy Derived Virtual Nonenhanced Computed Tomography Imaging: Current Status and Applications...
Next Document: Recognition of impaired atomoxetine metabolism because of low CYP2D6 activity.